Monique J. Roobol
Monique Roobol is Professor and the Head of the scientific research office within the Department of Urology at Erasmus Medical Centre Rotterdam, The Netherlands. She has a masters and a PhD degree in epidemiology.
The scientific research office performs and supports several clinical and population-based screening studies. She is responsible for the Dutch part of the European Randomized study of Screening for Prostate Cancer (ERSPC; www.erspc.org), the Prostate Cancer Research International Active Surveillance (www.prias-project.org) and the Movember Global Action Plan-3 (active surveillance). She is a board member of the ERSPC study group, the ERSPC Foundation as well as the Dutch Prostate Cancer Research Foundation (SWOP). She is also an active member of the Epidemiology Committee of the ERSPC. Her main interest is in predictive modeling (www.prostatecancer-riskcalculator.com) and has published over 280 scientific publications, book chapters and reviews.
Dr. Roobol’s research has been awarded with several prices, such as the bi-annual “van Stockum prize” from the Dutch Urological Association for best thesis, the EAU best clinical paper of the year 2009, the European Urology Platinum Award 2011 and the BJUI best urological mobile application award 2015.
Nicolas Mottet is a Professor at University Hospital St. Etienne, Urology St. Etienne and Head of the Urology Department, University Hospital St. Etienne and University Jean Monnet, Saint-Etienne, France. He is board certified in surgery, urology and medical oncology. He is chairman of the EAU Working Group on Prostate Cancer Guidelines, board member of the Urology Group for the French Anti-Cancer Centre Federation, and member of the SIOG prostate cancer guidelines. He is the former coordinator the Testis and Penile Cancer Subgroup (French Urological Association 2000 – 2008). Prof. Mottet has published over 245 peer-reviewed papers and made numerous presentations and lectures; he is member of the Editorial Board of the European Urology Journal and a reviewer of more than a dozen of high profile journals including the New England Journal of Medicine. He sits on the scientific advisory board of several multinational pharmaceutical companies. He coordinated or participated to more than 40 clinical trials and received several national grants. He is member of the AUA, EAU, AFU, ASCO, ESMO and SIOG.
William B. Isaacs
Dr. William B. Isaacs is a professor of urology and oncology at the Johns Hopkins School of Medicine. His primary research focus is hereditary prostate cancer. Dr. Isaacs’ team is working to characterize consistent alterations in the structure and expression of the genome of human prostate cancer cells as a way to identify genes that are critical in the pathways of prostatic carcinogenesis. The goal of this research is to more effectively identify men at high risk for prostate cancer and to identify new prognostic and therapeutic markers that could lead to more effective management of prostate cancer, and has published more than 400 peer-reviewed articles, book chapters and reviews.
Dr. Isaacs is recognized as a leader in the field of hereditary prostate cancer research. He has won numerous national and international awards and is a member of Sigma Xi, the American Society for Cell Biology, the Society for Basic Urologic Research and the American Association for Cancer Research.
G. Steven Bova
Steve Bova is a professor in the Prostate Cancer Research Center, Faculty of Medicine and Life Sciences, and at the BioMediTech Institute, University of Tampere,Institute of Biosciences and Medical Technology–BioMediTech, University of Tampere and Tampere University Hospital, Finland, leading the PELICAN- personalized cancer medicine group.
Prof. Bova has a medical training in pathology, surgery and urology, and has published more than 100 scientific papers, book chapters and reviews, focussing on the genomics underlying lethal prostate cancer. He has actively engaging in the implementation of translational cancer research studies and personalized medicine clinical trials, and is a PI of the International Cancer Genomics Consortium- Prostate Cancer.
Anders Bjartell is a Professor in Clinical Urology, Assistant Dean at the Medical Faculty, Lund University, and Senior Consultant at Skåne University Hospital in Malmö. He is also the past-president and board member of the European Association of Urology (EAU) Section of Urological Research (ESUR) and is currently Chairman of the EAU Research Foundation and a member of the EAU Guidelines Office Board.
Furthermore, Prof. Bjartell is national principal investigator for several trials of new drugs in castration‑resistant prostate cancer and Head of the clinical trial unit at the Urology Department at Skåne University Hospital. Prof. Bjartell leads a research group in translational prostate cancer research with long‑term experience in prostate cancer biomarkers and have participated in several EU-sponsored prostate cancer projects. He has published more than 230 peer‑reviewed articles.
L.A.L.M Kiemeney (Bart)
L.A.L.M Kiemeney (Bart) is professor at Faculty of Medical Sciences, associated with both the department of Epidemiologiy Biostatistics and Health Technology Assessment and the department of Urology at Radboud University, the Netherlands. He conducts epidemiological research on the development of bladder and prostate cancer focussing on hereditary sensitivity to these tumours and in lifestyles that increase the risk of tumors. Prof. Kiemeney has published more than 500 scientific articles, book chapters and reviews. Prof. Kiemeney is a member of the Scientific Council of the International Agency for Research in Cancer (WHO) in Lyons, France, and the Scientific Advisory Council on Cancer of the Dutch Cancer Society, and has received several awards, including Distinguished Researcher Award, European Society for Urological Research (ESUR).
Arena Heerschap is professor at Radboud University Nijmegen Medical Center, Department of Radiology. His main research interests are the application of Magnetic Resonance in oncology and in energy metabolism. He is a promoter of transfer of knowledge from basic biomedical research to clinical application. For these purposes he has initiated projects ranging from investigations on body fluids, tissue extracts and animal models up to examinations of human volunteers and patients. Prof. Heerschap has published more than 300 scientific papers, and has served in local and national scientific committees and in several committees of the ISMRM. Currently he is chair-elect of the Cancer study group of The International Society for Magnetic Resonance in Medicine (ISMRM). He is member of the executive board of the ESMRMB, member of the editorial board of MAGMA and a regular reviewer for several journals in the field of biomedical MR.
Steven Pennington a Professor of Proteomics in the School of Medicine and the UCD Conway Institute, a lead investigator in the Dublin based “Prostate Cancer Research Consortium” and established the core facility for proteomics at the UCD Conway Institute in 2003 and has a broad experience in discovering and quantification of protein biomarkers of clinical interest in oncology and inflammatory disease and to bring these into the clinic, with more than 240 peer-reviewed publications.
Prof. Pennington is on the editorial board of several journals including in a more senior capacity for 'Proteomics' and the 'Journal of Proteomics', Steve is a committee member of European Proteomics Association and vice-President of the British Society for Proteome Research.
Prof. Pennington has received a Sir Henry Wellcome Commemorative Award for Innovative Research, has been Director of Research and member of the Board of a Cambridge-based seed-corn funded fledgling biotech company and has served in small scale consultancy capacities for a number of commercial organizations.
Antoinette Perry is Lecturer at School of Biomolecular & Biomedical Science at the UCD Conway Institute, Dublin, Ireland. She has pioneered in translational prostate cancer epigenomics, centred around bridging the gap between the pathogenesis of prostate carcinogenesis and molecular prognostic biomarkers through epigenomic aberrations, primarily DNA methylation and ncRNAs. Dr. Perry is PI on several multi-institutional studies, including and Movember GAP1 urine biomarker project and in the Irish Programme for Stratified Prostate Cancer Therapies (iPROSPECT). Her work has led to more than 60 scientific publications and has been awarded the Prostate Cancer Foundations Young Investigators Award.
Jan Oldenburg is MD and Senior Consultant at the Akershus University Hospital. Dr. Oldenburg is focusing on urological cancers and is a panelist member of the EAU guidelines, member of the oncology Clinical Practice Guidelines Committee (ESMO) and member of the scientific committee of EMUC (European Multidisciplinary Meeting on Urological Cancers).